KalVista Pharmaceuticals has licensed commercialisation rights for sebetralstat, an oral on-demand treatment for hereditary ...

As KalVista Pharmaceuticals awaits an FDA decision on its hereditary angioedema (HAE) treatment sebetralstat, the company has ...

Dr. Sheri Yolanda Prentiss explores the challenges patients face in accessing lymphedema compression garments following ...

Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 months in early ...

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

The U.S. Food and Drug Administration (FDA) previously granted orphan drug designation to deucrictibant for the treatment of bradykinin-mediated angioedema in March 2022.

The following is a summary of “Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study,” ...

US-based biopharmaceutical company KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of ...

However, if the swelling and pain get worse or there are signs of infection, such as pus or discharge, a person may need medical treatment. A stye is an infection that occurs at the base of the ...

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient population UBX1325 was non-inferior to aflibercept at week 24 (>90% ...

The first in-human trials of an implantable device shows favorable safety and effectiveness in the treatment of corneal edema. The first in-human trials for an artificial lamellar implant (EndoArt, ...

and Pharming Group NV – aims to improve outcomes for HAE patients and advance clinical research for new treatment options to benefit patients around the globe. Hereditary angioedema is a rare genetic ...